Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
نویسنده
چکیده
Prostate cancer is the second leading cause of cancer death in men in the United States. Novel immunotherapies are being investigated to improve survival in patients with advanced disease. Sipuleucel-T (PROVENGE), the first autologous cellular immunotherapy approved by the U. S. Food and Drug Administration, improves survival in men with asymptomatic or minimally symptomatic metastatic castration-resistant (hormone refractory) prostate cancer.
منابع مشابه
Immunotherapy for Breast Cancer Treatment
Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...
متن کاملProstate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design
Prostate cancer is the second most diagnosed cancer in men and current treatment of advanced prostate cancer is ineffective. Immunotherapy has emerged as a promising treatment option for metastatic prostate cancer but its clinical application is still in the early stages of development. In order to treat metastatic prostate tumors, new directions must be taken to improve current immunotherapeut...
متن کاملSipuleucel-T: immunotherapy for advanced prostate cancer
Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being a...
متن کاملImmunotherapy for Prostate Cancer Enters Its Golden Age
In the United States, prostate cancer is the most frequent malignancy in men and ranks second in terms of mortality. Although recurrent or metastatic disease can be managed initially with androgen ablation, most patients eventually develop castration-resistant disease within a number of years, for which conventional treatments (eg, chemotherapy) provide only modest benefits. In the last few yea...
متن کاملاثر ایمونوتراپی سرطان پروستات بر بیان ژنesp انتروکوکوس فکالیس
Background: Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer deaths among men in the world. Immunotherapy is a new, non-invasive and effective method for the treatment of cancer, but its side effects on the normal flora of bacteria and opportunistic infections not known yet. The aim of this study was to evaluate the effects of immunotherapy on Ent...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Managed care
دوره 20 9 Suppl 5 شماره
صفحات -
تاریخ انتشار 2011